Results 81 to 90 of about 564,411 (195)

Selection and optimization strategy for Rap1-targeting single-domain antibodies as platelet activation markers. [PDF]

Res Pract Thromb Haemost
Alessi MC, Moulard M, Boulay-Moine D, Pons C, Margier M, Vessière C, Poggi M, Pigaglio T, Dignat-George F, Roussel A, Burtey S, Bonello L, Chames P, Bonjean R, Peiretti F.   +14 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

A synergistic generative-ranking framework for tailored design of therapeutic single-domain antibodies. [PDF]

Cell Discov
Kong Y, Shi J, Wu F, Zhao T, Wang R, Zhu X, Xu Q, Song Y, Li Q, Wang Y, Gao X, Yang Y, Feng Y, Wang Z, Ge W, Wu Y, Yang Z, Yao J, Ying T.   +18 more
europepmc   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting. [PDF]

Sci Rep
Altunay B, Obradović L, Florea A, Vogg ATJ, Schäfer L, Morgenroth A, Meszaros LK, Hertel F, Juweid ME, Mottaghy FM.   +9 more
europepmc   +1 more source

Structure–Function Decoupling of the Sensorimotor and Default Mode Networks in Black Americans With MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Multiple sclerosis (MS) exhibits racially disparate rates of disease progression. Black people with MS (B‐PwMS) experience a more severe disease course than non‐Hispanic White people with MS (NHW‐PwMS). Here we investigated structural and functional connectivity as well as structure–function decoupling in the ...
Emilio Cipriano, Giacomo Boffa, Maria Petracca, Marta Ponzano, Nicole Graziano, Claire Wigley, Claire Riley, Jonathan Howard, Pietro Bontempi, Sylvia Klineova, Fred Lublin, Matilde Inglese   +11 more
wiley   +1 more source

Improving the solubility of single domain antibodies using VH-like hallmark residues. [PDF]

Protein Sci
Uto Y, Nakakido M, Yokoo T, Fernandez-Perez J, Entzminger K, Maruyama T, Okumura CJ, Kuroda D, Caaveiro JMM, Tsumoto K.   +9 more
europepmc   +1 more source

Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina, Anna Marcé‐Grau, Barbara Masotto, Marta Codina, Lamia BenJemaa, Yasmina Elaribi, Mónica Martinez‐Gallo, Roger Colobran, Angel Sanchez‐Montañez, Irene Valenzuela, Yoshiko Murakami, Alfons Macaya   +11 more
wiley   +1 more source

Unlocking binding properties of single-domain antibodies targeting the polymeric immunoglobulin receptor to enhance mucosal enrichment of IgG against respiratory syncytial virus. [PDF]

Front Immunol
Liu J, Jung J, Zhou S, Chen SJ, Huang J, Tang Y, Vroom K, Motlagh S, Chen D, Trinh H, Worthington P, Ma DY, Wen Z, Luo B, Yadav DB, Phuah JY, Chen Z, Vora KA, Handa M.   +18 more
europepmc   +1 more source

Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies. [PDF]

PLoS One, 2023
Debatis M, Danz H, Tremblay JM, Gaspie K, Kudej RK, Vigdorovich V, Sather N, Jaskiewicz JJ, Tzipori S, Shoemaker CB.   +9 more
europepmc   +1 more source